Relevant factors for neurologists to define effectiveness of migraine preventive drugs and take decisions on treatment. My-LIFE European Delphi survey.

MLA

Pozo-Rosich, Patricia, et al. “Relevant Factors for Neurologists to Define Effectiveness of Migraine Preventive Drugs and Take Decisions on Treatment. My-LIFE European Delphi Survey.” European Journal of Pain (London, England), vol. 25, no. 10, Nov. 2021, pp. 2177–89. EBSCOhost, https://doi.org/10.1002/ejp.1831.

APA

Pozo-Rosich, P., Gil-Gouveia, R., Donnet, A., Poole, A.-C., Gendolla, A., Afridi, S., Sanchez-De la Rosa, R., Terwindt, G. M., & Tassorelli, C. (2021). Relevant factors for neurologists to define effectiveness of migraine preventive drugs and take decisions on treatment. My-LIFE European Delphi survey. European Journal of Pain (London, England), 25(10), 2177–2189. https://doi.org/10.1002/ejp.1831

Chicago

Pozo-Rosich, Patricia, Raquel Gil-Gouveia, Anne Donnet, Anne-Christine Poole, Astrid Gendolla, Shazia Afridi, Rainel Sanchez-De la Rosa, Gisela M Terwindt, and Cristina Tassorelli. 2021. “Relevant Factors for Neurologists to Define Effectiveness of Migraine Preventive Drugs and Take Decisions on Treatment. My-LIFE European Delphi Survey.” European Journal of Pain (London, England) 25 (10): 2177–89. doi:10.1002/ejp.1831.